Pharmacological Evaluation of Jambrushila Tablet on Animal Model of Type-2 Diabetes

Abstract

The study was undertaken to obtain the scientific evidence to the efficacious claim of the use of Jambrushila Tablet in the management of type-2 diabetes. The SD rats were divided into 4 groups: normal control, disease control, diseased treated with metformin (10mg/kg) and diseased treated with Jambrushila Tablet (100 mg/kg). Type 2 diabetes was induced in male Sprague Dawley rats by feeding them a high-fat diet in combination streptozotocin (35 mg/kg). Treatment was given for a period of 4 weeks. Insulin resistant rats developed characteristic features with insulin resistance syndrome such as hyperglycemia, hyperinsulinemia hypertriglyceridemia, hypercholesterolemia, glucose intolerance. Treatment with formulation and metformin exhibited significant decrease in body weight, serum glucose and insulin levels as compared to disease control rats. Following the administration of formulation and metformin, it was observed that there was an increase in HDL levels and decrease in the serum cholesterol, triglyceride, LDL-cholesterol and VLDL-cholesterol levels when compared to disease control group. The treatment also exhibited significant reduction in AUCglucose and AUCinsulin in oral glucose tolerance test. Homeostasis model assessment of insulin resistance (HOMAIR) and quantitative insulin sensitivity check index (QUICKI) were found to be significantly improved without significant modification of fasting glucoses to insulin ratio (FGIR) and HOMA-β index. Our findings indicate that Jambrushila Tablet can be beneficial for treatment of hyperglycemia and hyperlipidemia associated with type-2 diabetes.